SCLX Live signaler | Maksimer profitt med Getagraph.com

SELG 155774 min ago

@ $1.570

Utstedt: 13 feb 2024 @ 22:00

Avkastning: -31.21%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -2.45 %

Live Chart Being Loaded With Signals

Commentary (31 mai 2024 @ 22:00):

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain...

Stats
Dagens volum	434 162
Gjennomsnittsvolum	1.06M
Markedsverdi	195.69M
EPS	$0 ( 2024-05-10 )
Neste inntjeningsdato	( $-0.180 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.830
ATR14	$0.00600 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-17	Ji Henry	Buy	50 000	Common Stock
2024-05-17	Chun Jay	Buy	57 500	Common Stock
2024-05-17	Shah Jaisim	Buy	56 939	Common Stock
2024-05-16	Shah Jaisim	Buy	83 061	Common Stock
2024-05-17	Ma Stephen Hoi	Buy	14 140	Common Stock

INSIDER POWER
-85.35
Last 53 transactions
Buy: 18 104 987 \| Sell: 160 710 385

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: -0.57 (weak negative)

Signal:(50.451) Neutral

Scilex Holding Company Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Scilex Holding Company Korrelasjon - Valuta/Råvare

-0.24
( neutral )

-0.18
( neutral )

0.00
( neutral )

-0.12
( neutral )

0.09
( neutral )

Scilex Holding Company Økonomi

Annual	2023
Omsetning:	$46.74M
Bruttogevinst:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2023
Omsetning:	$46.74M
Bruttogevinst:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2022
Omsetning:	$38.03M
Bruttogevinst:	$27.24M (71.61 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Scilex Holding Company Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.